Lundquist Institute Investigator is Lead Author on a JAMA Open Network Publication that Positively Evaluates EyeArt AI System to Prevent Diabetic Vision Loss – Yahoo Finance

Is the fossil fuel recovery real, or a stepping stone to a fossil-free future? Register now for our 11/17 webinar at 2PM ET
The study examines performance of the EyeArt AI system for detecting eyes with more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR)
LOS ANGELES, Nov. 16, 2021 /PRNewswire/ — The Lundquist Institute's Investigator Eli Ipp, MD, and a multi-center team of investigators have evaluated the performance of the EyeArt AI system in a study published in JAMA Open Network. Dr. Ipp and his co-investigators found that the accuracy of the EyeArt AI system was high in detecting mtmDR (sensitivity 96% and specificity 88%) and vtDR (sensitivity 97% and specificity 90%). The study demonstrates the ability of the EyeArt system to accurately detect mtmDR and vtDR without physician oversight or the need for dilation in most individuals, thus facilitating diabetic eye exams at non-specialist facilities and enabling accelerated referral of vision-threatening diabetic retinopathy. This is the first AI-based system that identifies vtDR, the most serious form of DR that puts patients at highest risk of blindness. The strong results from the EyeArt prospective, multicenter pivotal clinical trial (NCT03112005) were published as an original investigation in JAMA Network Open, a peer-reviewed medical journal published by the American Medical Association. The article is titled "Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-threatening Diabetic Retinopathy.
"Over four hundred million people around the world have diabetes and approximately one-third of them may develop diabetic retinopathy, which is the leading cause of vision loss among working-age adults in most countries," said Eli Ipp, M.D., Investigator at The Lundquist Institute, Professor of Medicine, David Geffen School of Medicine at UCLA, Head of the Section of Diabetes and Metabolism at Harbor-UCLA Medical Center, and the first author of the EyeArt publication on JAMA Network Open. "By simplifying and improving the efficiency of diabetes retinal screening, the EyeArt technology has the potential to contribute to saving vision for millions of people around the world. The EyeArt pivotal trial was well designed and executed, and we are gratified that it is now published by JAMA Network Open."
The EyeArt® AI System was developed by Eyenuk, Inc. with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS).
Contact for The Lundquist Institute:
Max Benavidez [email protected] 310-200-2682
View original content:https://www.prnewswire.com/news-releases/lundquist-institute-investigator-is-lead-author-on-a-jama-open-network-publication-that-positively-evaluates-eyeart-ai-system-to-prevent-diabetic-vision-loss-301426027.html
SOURCE The Lundquist Institute
Vitacore Industries Inc. has announced it will be opening a full-scale production facility in Saskatchewan for the manufacturing of medical equipment and PPE in 2022. This information was shared by the Honourable Jim Reiter, minister of SaskBuilds and Procurement, when he introduced Mikhail Moore, president of Vitacore, and John Sprague, director of operations, at the Saskatchewan Legislature this afternoon.
Shares of Kezar Life Sciences (NASDAQ: KZR) were soaring 36.1% as of 11:03 a.m. EST on Tuesday. The big gain came after the company announced interim results on Monday from a phase 2 study evaluating KZR-616 in treating autoimmune disease lupus nephritis. With the huge move for the biotech stock today, it's not surprising that Kezar's results were really good.
Dr. Ali Raja, professor at Harvard Medical School, talks about how Pfizer's new treatment is another added tool that can fight breakthrough cases and turn the tide against COVID-19.
The surprisingly big jump in Medicare Part B premiums for 2022 reflects the sky-high cost of a controversial Alzheimer’s disease drug. The premium hike will put more than a dent in the newly increased Social Security cost-of-living allowance, which worked out … Continue reading → The post Why 2022 Medicare Part B Premiums Soared appeared first on SmartAsset Blog.
Shares of Tonix Pharmaceuticals (NASDAQ: TNXP), a much-discussed title among the meme stock crowd, had the latest in a series of up-and-down trading days on Monday. The biotech's stock flew nearly 7% higher on the back of encouraging patent news. Tonix announced that last Tuesday, it received a patent for "Trefoil Family Factor Proteins and Uses Thereof."
U.S. marijuana stocks were up on Monday, ahead of an expected unveiling of Republican-led draft legislation to legalize cannabis in the U.S.
Is Pfizer stock a buy after its Covid pill cuts hospitalizations and deaths by 89% in a key study? Is PFE stock a buy right now?
Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday. AbbVie Inc's widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.
Al Sandrock, the head of R&D and longtime chief medical officer at Biogen Inc., is set to retire at the end of this year.
Dr. Alfred Sandrock, the man most closely associated with Biogen's controversial Alzheimer’s disease therapy, Aduhelm, will retire at the end of the year.
Is Merck stock a buy after its Covid pill, molnupiravir, offers a new hope in the fight against Covid-19? Is MRK stock a buy now?
Pfizer stock inched lower Tuesday after the company asked the Food and Drug Administration to authorize its Covid pill for emergency use.
The NIH disagrees with Moderna over who deserves credit for inventing the company's COVID-19 vaccine.
More than 30 million people in the U.S. have gotten a booster COVID shot already, according to the latest data from the Centers for Disease Control and Prevention (CDC). Only some people are technically eligible for an additional shot right now, as both the CDC and the U.S. Food and Drug Administration (FDA) are still deliberating opening up qualifications for third doses. Several states, including New York, Colorado, New Mexico, and Arkansas, have recently bypassed these agencies, however, and
The company is exiting early research and looking for "other opportunities" that complement its work in cancer.
Africa Health Holdings, a healthcare startup running several hospitals, has secured $18 million in a Series A round, funds that will go toward building its “tech-forward healthcare system” across Ghana, Kenya and Nigeria. The funding round, led by Asia Pacific Land and Natural World Limited, saw the participation of a number of investors including TRB Advisors, Breyer Capital, M3, Inc., Valiant Capital, Kepple Ventures and SUNU Capital. Africa Health Holdings, based in West Africa, will use the new capital to expand its telemedicine service beyond Ghana, to countries like Nigeria and Kenya.
The company's filing comes as new infections are rising once again, driven mainly by hot spots in states where colder weather is driving more Americans indoors.
Pfizer and Moderna announced moves early Tuesday that will support the effort to get vital medicines to lower-income countries to help them battle COVID-19, securing supplies of the former's antiviral treatment and the latter's vaccine.
Kidney infections usually happen when a bladder infection has gone untreated. Here's how to recognize the symptoms and get treated ASAP.
Anti-vaccination sentiment in the U.S. has taken off amid the increase in COVID-19 vaccine mandates across the country.

source